GW Pharmaceutical

GW Pharmaceuticals Stock Soaring and Spurring on Bullish Calls After Q1

GWPH Profile

  • Sector: Health Technology
  • Industry: Pharmaceuticals: Other
  • Employees: 901

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Recent News

GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine Email Print Friendly ShareSeptember 23, 2020 03:54 ET | Source: GW Pharmaceuticals plc LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that theContinue reading “GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy”

Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020

– Nearly one-third of survey respondents indicated use of THC-containing cannabis for Multiple Sclerosis (MS) symptom management — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, will present results of a survey conducted inContinue reading “Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020”

FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease

— Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) andContinue reading “FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease”

Loading…

Something went wrong. Please refresh the page and/or try again.